Accueil › Cancer du rein (carcinome à cellules rénales) › Texas › Dallas
Essais cliniques pour Cancer du rein (carcinome à cellules rénales) à Dallas, TX
23 études pour Cancer du rein (carcinome à cellules rénales) recherchent des participants dans et autour de Dallas (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Recrutement en coursPhase 1
- NEO-811 Dallas Site, Dallas
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Recrutement en coursPhase 1
- Texas Oncology, Dallas
- University of Texas Southwestern Medical Center, Dallas
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Recrutement en coursPhase 1
- Exelixis Clinical Site #89, Dallas
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Recrutement en coursPhase 2
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
DESTINY-PANTUMOUR04
Recrutement en coursÉtude observationnelle
- Research Site, Dallas
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Recrutement en coursPhase 1/2
- Baylor, Scott and White Research Institute, Dallas
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Recrutement en coursPhase 2
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Recrutement en coursPhase 1/2
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- University of Texas Southwestern Medical Center-William P. Clements Jr. University Hospital, Dallas
- University of Texas Southwestern Simmons Cancer Center - Redbird, Dallas
- et 2 autres
Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
Recrutement en coursPhase 2
- University of Texas Southwestern Medical Center, Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recrutement en coursÉtude observationnelle
- UT Southwestern Medical Center, Dallas
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Recrutement en coursPhase 1/2
- Mary Crowley Cancer Research, Dallas
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Recrutement en coursPhase 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Recrutement en coursPhase 2
- University of Texas, Southwestern Medical Center, Dallas
PET/MR for Characterization of Renal Masses (RMs)
Recrutement en coursÉtude observationnelle
- University of Texas Southwestern Medical Center, Dallas
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Recrutement en coursPhase 1
- UT Southwestern Simmons Cancer Center, Dallas
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Recrutement en coursPhase 1
- University of Texas Southwestern Medical Center /ID# 251974, Dallas
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Recrutement en coursPhase 2
- UT Southwestern Medical Center, Dallas
A Study of VET3-TGI in Patients With Solid Tumors
Recrutement en coursPhase 1
- Mary Crowley Cancer Research, Dallas
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
Recrutement en coursVolontaires sains bienvenus
- University of Texas Southwestern Medical Center, Dallas
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
Recrutement en coursPhase 1
- UT Southwestern Medical Center, Dallas
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
Recrutement en coursPhase 2
- University of Texas Southwestern Medical Center, Dallas
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
Recrutement en coursPhase 2
- UT Southwestern Medical Center, Dallas
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Recrutement en coursPhase 3
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Essais pour Cancer du rein (carcinome à cellules rénales) dans d'autres villes
- Houston, TX35 études
- New York City, NY27 études
- Nashville, TN23 études
- St. Louis, MO23 études
- Los Angeles, CA20 études
- Boston, MA16 études
- Baldwin Park, CA16 études
- Philadelphia, PA15 études
- Pittsburgh, PA15 études
- Queens, NY15 études
- Jacksonville, FL14 études
- Rochester, MN14 études
Autres études à Dallas
- Cancer du sein55 études
- Cancer du poumon non à petites cellules52 études
- Cancer métastatique42 études
- Insuffisance cardiaque42 études
- Cancer (tous types)37 études
- Cancer de la prostate36 études
- Cancer colorectal33 études
- Obésité30 études
- Cancer de l'ovaire28 études
- Cancer du poumon27 études
- Cancer de la vessie27 études
- Cancer de l'endomètre24 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.